What is BREZTRI Aerosphere?
BREZTRI Aerosphere is an inhalation aerosol used for the maintenance (long-term) treatment of Chronic Obstructive Pulmonary Disorder (COPD) in adults. It is a prescription drug that contains a combination of three active ingredients: budesonide, glycopyrrolate, and formoterol fumarate.
BREZTRI Aerosphere works by reducing inflammation and opening the airways, making it easier for the patient to breathe. It is also designed to help prevent exacerbations or flare-ups of COPD symptoms.
It is important to follow the dosing instructions carefully to get the most benefit from BREZTRI Aerosphere. The recommended dose is two inhalations twice daily, approximately 12 hours apart. The inhaler should be primed before the first use by releasing a spray into the air away from the patient's face.
BREZTRI Aerosphere is manufactured by AstraZeneca, a pharmaceutical company that specializes in the development of drugs for respiratory diseases. It was approved by the U.S. Food and Drug Administration (FDA) in July 2020.
Like any medication, BREZTRI Aerosphere can cause side effects, such as headache, cough, and a change in taste. However, in clinical studies, the side effects were generally mild and well-tolerated by patients. It is important to discuss any concerns about potential side effects with a healthcare professional before using BREZTRI Aerosphere.
Overall, BREZTRI Aerosphere is a treatment option for COPD that may help patients manage their symptoms and reduce the risk of exacerbations. As with any medication, it is important to use it as directed and report any unexpected or concerning symptoms to a healthcare provider.
Frequently Asked Questions about breztri aerosphere
BREZTRI AEROSPHERE is a medicine used long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups. BREZTRI is not used to relieve sudden breathing problems and will not replace a rescue inhaler.
BREZTRI combines 3 medicines, an inhaled corticosteroid (ICS) medicine (budesonide), an anticholinergic medicine (glycopyrrolate), and a long acting beta2-adrenergic agonist (LABA) medicine (formoterol fumarate) in one inhaler.
AstraZeneca plans to build a manufacturing facility in Qingdao, China, to produce its Breztri aerosol inhalant COPD treatment, which was recently added to the country's National Reimbursement Drug List.
AstraZeneca's Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
BREZTRI is used long term as 2 inhalations 2 times each day (2 puffs in the morning and 2 puffs in the evening) to improve symptoms of COPD for better breathing*,† and to reduce the number of flare-ups*,† (the worsening of your COPD symptoms for several days).
Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics.
BREZTRI is used long term as 2 inhalations 2 times each day (2 puffs in the morning and 2 puffs in the evening) to improve symptoms of COPD for better breathing*,† and to reduce the number of flare-ups*,† (the worsening of your COPD symptoms for several days).
Breztri Aerosphere only comes as a brand-name drug. It's not currently available in a generic version. A generic drug is an exact copy of the active drug in a brand-name medication. Generics tend to cost less than brand-name drugs.
July 2020
Breztri Aerosphere was approved in July 2020 for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Breztri was not indicated for the relief of acute bronchospasm or for the treatment of asthma.
Breztri Aerosphere (budesonide, glycopyrrolate, and formoterol fumarate) is a combination of an inhaled corticosteroid, an anticholinergic, and a long-acting beta2-adrenergic agonist (LABA), indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Breztri Aerosphere has an average rating of 6.9 out of 10 from a total of 50 reviews on Drugs.com. 60% of reviewers reported a positive experience, while 22% reported a negative experience.
Breztri Aerosphere
- Generic Name: budesonide, glycopyrrolate, and formoterol fumarate inhalation aerosol.
- Brand Name: Breztri Aerosphere.
- Drug Class: Anticholinergic Agents, Beta2 Agonists.
Breztri contains budesonide, glycopyrrolate, and formoterol fumarate. Symbicort contains two of these active drugs: budesonide and formoterol fumarate. Symbicort and Breztri Aerosphere are each approved for maintenance (long-term) treatment of chronic obstructive pulmonary disease (COPD) in adults.
The average cost for 1 Inhaler, 10.7gm of 160-9-4.8mcg/act each, is $751.62. You can buy Breztri Aerosphere at the discounted price of $633.84 by using the WebMDRx coupon, a savings of 16%. Even if this drug is covered by Medicare or your insurance, we recommend you compare prices.
Mechanism of Action
Breztri Aerosphere is a combination of budesonide, glycopyrrolate, and formoterol fumarate. The mechanism of action for the individual components are described below: Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity.
Breztri Aerosphere has an average rating of 6.7 out of 10 from a total of 58 ratings on Drugs.com. 60% of reviewers reported a positive effect, while 22% reported a negative effect. Symbicort has an average rating of 6.5 out of 10 from a total of 217 ratings on Drugs.com.
